Dr. Reddy's Laboratories Limited
National Stock Exchange of IndiaTotal Valuation
Dr. Reddy's Laboratories Limited carries a market capitalization of 1.05T, placing it among publicly traded companies globally. Its enterprise value stands at 1.04T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.05T |
| Enterprise Value | 1.04T |
Share Statistics
Dr. Reddy's Laboratories Limited currently has 832.45M shares outstanding.
| Shares Outstanding | 832.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Dr. Reddy's Laboratories Limited trades at a trailing price-to-earnings ratio of 24.38. The price-to-sales ratio is 3.11, and the price-to-book ratio stands at 2.96.
| PE Ratio | 24.38 |
| PS Ratio | 3.11 |
| PB Ratio | 2.96 |
| P/TBV Ratio | 3.98 |
| P/FCF Ratio | 10.99 |
| P/OCF Ratio | 18.41 |
Enterprise Valuation
On an enterprise value basis, Dr. Reddy's Laboratories Limited trades at an EV/EBITDA multiple of 18.72 and an EV/FCF ratio of 10.58. The EV/Sales ratio of 3.09 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.81 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.09 |
| EV / EBITDA | 18.72 |
| EV / EBIT | 20.81 |
| EV / FCF | 10.58 |
Financial Position
Dr. Reddy's Laboratories Limited maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.33, indicating elevated leverage, while an interest coverage ratio of 14.83 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.80 |
| Quick Ratio | 1.26 |
| Debt / Equity | 20.33 |
| Debt / EBITDA | 1.39 |
| Interest Coverage | 14.83 |
Financial Efficiency
Dr. Reddy's Laboratories Limited posts a return on equity of 12.80 and a return on invested capital of 9.14.
| Return on Equity (ROE) | 12.80 |
| Return on Assets (ROA) | 7.99 |
| Return on Invested Capital (ROIC) | 9.14 |
| Return on Capital Employed (ROCE) | 11.52 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.44 |
Taxes
Over the trailing twelve months, Dr. Reddy's Laboratories Limited has paid 12.35B in income taxes, reflecting an effective tax rate of 22.53.
| Income Tax | 12.35B |
| Effective Tax Rate | 22.53 |
Stock Price Statistics
Dr. Reddy's Laboratories Limited's stock has gained approximately 1.20163% over the past 52 weeks. The 50-day moving average sits at 1,278.44, while the 200-day moving average is 1,263.13.
| Beta (5Y) | N/A |
| 52-Week Price Change | 1.20163% |
| 50-Day Moving Average | 1,278.44 |
| 200-Day Moving Average | 1,263.13 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Dr. Reddy's Laboratories Limited generated 335.93B in revenue and converted that into 42.86B in net income, yielding earnings per share of 50.97. EBITDA reached 55.44B, while operating income came in at 49.87B.
| Revenue | 335.93B |
| Gross Profit | 186.61B |
| Operating Income | 49.87B |
| Pretax Income | 54.82B |
| Net Income | 42.86B |
| EBITDA | 55.44B |
| EBIT | 49.87B |
| Earnings Per Share (EPS) | 50.97 |
Balance Sheet
Dr. Reddy's Laboratories Limited holds 87.81B in cash and equivalents against 77.34B in total debt, resulting in a net debt position of 59.77B. Total book value stands at 352.82B, with working capital of 134.41B providing operational flexibility.
| Cash & Cash Equivalents | 87.81B |
| Total Debt | 77.34B |
| Net Debt | 59.77B |
| Equity (Book Value) | 352.82B |
| Book Value Per Share | 423.68 |
| Working Capital | 134.41B |
Cash Flow
Dr. Reddy's Laboratories Limited produced 56.76B in operating cash flow over the past twelve months. After subtracting -38.42B in capital expenditures, free cash flow totaled 18.33B - equivalent to 22.01 per share.
| Operating Cash Flow | 56.76B |
| Capital Expenditures | -38.42B |
| Free Cash Flow | 18.33B |
| FCF Per Share | 22.01 |
Margins
Dr. Reddy's Laboratories Limited operates with a gross margin of 90.44, reflecting its pricing power and cost economics. The operating margin of 14.84 and net profit margin of 12.76 provide insight into operational efficiency.
| Gross Margin | 90.44 |
| Operating Margin | 14.84 |
| Pretax Margin | 16.32 |
| Profit Margin | 12.76 |
| EBITDA Margin | 16.50 |
Dividends & Yields
The company's payout ratio of 15.82 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 8.00 |
| Dividend Yield | N/A |
| Payout Ratio | 15.82 |
| Shareholder Yield | -0.79 |
| FCF Yield | 9.10 |
Stock Splits
Dr. Reddy's Laboratories Limited's most recent stock split took place on October 28, 2024 with a 1:5 split ratio.
| Last Split Date | 10/28/2024 |
| Split Ratio | 1:5 |
Scores
Dr. Reddy's Laboratories Limited posts an Altman Z-Score of 5.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.65 |